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Extracellular vesicles (EVs) secreted by cells present an attractive
strategy for developing new therapies, but progress in the field is
limited by several issues: The quality of the EVs varies with the
type and physiological status of the producer cells; protocols used
to isolate the EVs are difficult to scale up; and assays for efficacy
are difficult to develop. In the present report, we have addressed
these issues by using human mesenchymal stem/stromal cells (MSCs)
that produce EVs when incubated in a protein-free medium, pre-
selecting the preparations of MSCs with a biomarker for their potency
in modulating inflammation, incubating the cells in a chemically
defined protein-free medium that provided a stable environment, iso-
lating the EVs with a scalable chromatographic procedure, and de-
veloping an in vivo assay for efficacy of the cells in suppressing
neuroinflammation after traumatic brain injury (TBI) in mice. In
addition, we demonstrate that i.v. infusion of the isolated EVs shortly
after induction of TBI rescued pattern separation and spatial learn-
ing impairments 1 mo later.
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Traumatic brain injury (TBI) has devastating effects on thevictims and creates a large burden on the healthcare system
(1). TBI was originally considered an acute injury syndrome, but
it is now recognized to have chronic effects similar to those found
in neurodegenerative disorders (2–5). In the acute phase, the
trauma destroys tissue, and it also triggers a cascade of events that
include excessive neural excitability, oxidative stress, disruption of
the blood–brain barrier, and inflammation. The cascade causes
additional cell death that occurs through necrosis, apoptosis, and
excessive autophagy. The cascade involves astrocytes and micro-
glia, in addition to invading neutrophils, monocytes/macrophages,
and T cells. The sequence of events is similar to the sequence seen
with sterile injuries to other tissues. Initially, proinflammatory effects
predominate and are useful in clearing tissue debris. Thereafter,
there is a transition to an antiinflammatory phase, with the microglia
and macrophages transiting from “classical” proinflammatory M1
phenotype to multiple alternative M2 phenotypes that suppress the
M1 proinflammatory mediators and enhance tissue repair. The
chronic effects of TBI occur because the inflammatory phase is not
fully suppressed. Instead, the inflammatory responses persist, and
they initiate a self-perpetuating cycle of tissue destruction, followed
by further inflammation. A similar cycle is now recognized to con-
tribute to the pathology of many chronic diseases.
Multiple strategies have been tested to modulate inflammation in
TBI and other CNS disorders (2–4). Among these strategies is the
use of mesenchymal stem/stromal cells (MSCs) from bone marrow
and other tissues (6–19). The beneficial effects of the MSCs are
probably explained by their normal roles as perivascular cells that
are among the first responders to tissue injury. One of their re-
sponses is to act in concert with other cells as guardians of excessive
inflammation because they are activated by proinflammatory cyto-
kines such as TNF-α to secrete modulators of inflammation that
include TNF-alpha stimulated gene/protein 6 (TSG-6), PGE-2,
STC-1, IL-1 receptor antagonist, and TIMP3 (18, 20–25).
Recently, we have explored the hypothesis that extracellular
vesicles (EVs) produced by MSCs may be an effective therapy
for TBI because extensive recent reports indicate that EVs may
provide a highly efficient means of delivering therapeutic factors
to target cells (26–29). As noted by György et al. (29), there are
several issues that currently limit therapeutic applications of
EVs. In the present report, we have addressed most of these
issues. In addition, we demonstrate the efficacy of EVs isolated
from MSCs in a mouse model for TBI. As this work was in
progress, Zhang et al. (30) reported that exosomes isolated from
MSCs improved functional recovery in a rat model for TBI, but
they did not characterize the exosomes.
Results
Selection of Optimal MSCs and Culture Conditions for Production of
EVs. Preparations of tissue-derived MSCs vary in their charac-
teristics dependent on undefined properties of the human donor
of the tissue and the site from which the cells are obtained from
the same donor (31–34). Therefore, we selected a preparation of
bone marrow MSCs (defined as donor 6015), from our NIH-
sponsored center for distribution of MSCs, that met the classical
in vitro criteria for MSCs and that ranked among the top 3 of 13
MSC preparations in expression of the biomarker of mRNA for
TSG-6 that was highly correlated with the efficacy of the cells in
modulating inflammation in three murine models (34). MSCs
also vary with culture conditions, such as cell densities, and the
culture medium (6). To reduce the variability, we followed a pro-
tocol in which the MSCs were consistently plated at 500 cells per
cm2 in a standardized medium (21–24) containing 17% of a pre-
tested batch of FBS [defined as complete culture medium (CCM)].
The CCM was replaced after 2 or 3 d. After 5 d, the medium was
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changed to a proprietary chemically defined and protein medium
(CDPF) that was initially optimized by a commercial supplier for
production of recombinant proteins by Chinese hamster ovary cells
(Invitrogen). We further supplemented the medium (Table S1) to
minimize aggregation of cells secreting TSG-6 by cross-linking
hyaluronan on the cell surface. As a convenient marker for EVs,
we used assays for CD63 (Fig. S1), a tetraspan protein frequently
found in EVs (26–29). Culture of MSCs in the CDPF medium
increased the expression of mRNA for CD63 (Fig. 1A). The ex-
pression of the mRNA increased for at least 48 h and was ac-
companied by the accumulation of the CD63 protein in the
medium (Fig. 1 B and C). However, the pattern of genes expressed
differed during the time of incubation in the CDPF. At 2 h, there
was a high level of expression of mRNA for IL-1β, a major
proinflammatory cytokine. In contrast, expression of mRNA for
the inflammation-modulating protein TSG-6 was low at 2 h and
increased progressively at 6, 24, and 48 h (Fig. 1 D and E). The
TSG-6 protein in medium did not increase until about 48 h (Fig.
1F). On the basis of these observations, we developed a standardized
protocol for production on EVs that might have antiinflammatory
properties (Fig. 1G). The MSCs did not expand, but there was
little evidence of cell death (Fig. 2A). Comparison of preparations
of MSCs demonstrated that the levels of CD63 protein in the
harvested medium were higher in MSCs from donor 6015, the
preparation initially selected here, than in three other preparations
(Fig. 2 B, i). As expected, the level of TSG-6 in the harvested
medium was the highest in donor 6015 (compare Fig. 2 B, ii, with
figure 4A in ref. 34).
Isolation of EVs with a Scalable Protocol. Most of the published
protocols for isolation of EVs involve high-speed centrifugation
or other procedures that cannot be readily scaled up for large-
scale production (29). To develop a scalable protocol, we isolated
EVs from the harvested medium by chromatography. In a small-
scale test, we found that most of the protein in the harvested
medium bound to an anion exchange resin but that little bound to
a cation exchange resin (Fig. 2C). Therefore, we developed a
Fig. 1. Defining conditions for production of EVs. Cultures of human MSCs
(donor 6015) at 70–80% confluent were transferred to the media indicated
and incubated for 6–48 h. (A) Expression of mRNA for CD63 was increased by
culture for 48 h in CDPF medium compared with culture in CCM with stan-
dard concentration of FBS (16.6%) or reduced FBS (2%). Assay by RT-PCR.
(B) Expression of mRNA for CD63 was increased with time of incubation in
CDPF. (C) Secretion of CD63+ was increased with time in CDPF. Medium was
assayed by ELISA for vesicle-bound protein (Fig. S1). (D) RT-PCR assays in
MSCs incubated in CDPF indicated that the proinflammatory cytokine IL-1β
was expressed for up to 6 h and that expression of the inflammation-mod-
ulating protein TSG-6 increased between 2 and 24 h. Expression of the
antiapoptotic/calcium-phosphate metabolic protein STC-1 peaked at about 6
h. (E) Expression of mRNA for TSG-6 increased with time of incubation in
CDPF. (F) Secretion of TSG-6 increased with time in CDPF. Assay by ELISA.
(G) Schematic for protocol developed for production of EVs by MSCs.
Fig. 2. Survival of the MSCs under the culture conditions, comparisons of
four donors, and demonstration that most of the secreted proteins and EVs
are anionic. (A) Survival of MSCs in CDPF. MSCs were expanded to about
70% confluence and then incubated an additional 48 h in CCM, CDPF, or
PBS. (Top) Cultures labeled with Hoechst, Calcein AM, and propidium iodide
(PI) demonstrate viable cells in CDPF but not PBS. (Bottom) Assays of the same
cultures by flow cytometry after labeling with PI and Annexin V demonstrated
survival in CCM or CDPF medium but not PBS. (B) Comparisons of four dif-
ferent preparations of MSCs (donors 235, 6015, 7052 and 7074) after in-
cubation as in Fig. 1G. (i) CD63+ in medium assayed by ELISA. (ii) TSG-6 in
medium assayed by ELISA. (C) Small-scale assays in SDS-electrophoretic gels
demonstrated that most of the medium proteins bound to and were eluted
from an anionic resin and not a cationic resin. Gels were stained with silver.
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protocol in which the harvested medium was centrifuged at 2,500 × g
for 15 min and the supernatant was chromatographed on an anion
exchange column. The protein eluted with 0.5 M NaCl was re-
covered as a single broad peak that contained CD63 (Fig. 3 A,
i and ii). The recovery of CD63 in the peak ranged from 73% to
81% (n = 3) and was slightly higher than was obtained by
centrifuging the harvested medium at 100,000 × g for 12 h (Fig.
3B). Assay of the peak fractions with a nanoparticle tracking
system (Fig. 3C) demonstrated that they contained about 0.51 ×
109 vesicles per microgram of protein. Assays at decreasing con-
centrations indicated that the mean size of the vesicles was 231 ±
3.2 nm (SEM), 216 ± 2.3 nm, and 207 ± 1.8 nm, respectively.
Interestingly, the three peaks observed at the lowest concentra-
tion were 85, 165, and 236 nm, the expected sizes of EVs of 85 nm
that were also recovered as dimers and trimers.
Surface Epitopes of the Isolated EVs. To map surface epitopes, we
used a previously published method (35) whereby EVs are first
trapped with a large bead linked to an antibody to CD63, and
then additional epitopes on the trapped EVs are assayed with
standard protocols for flow cytometry. As expected, the EVs
captured with the protocol were positive for CD63 (Fig. S2).
They were also about 80% positive for CD81, another epitope
frequently found on EVs (26–29). However, they were nega-
tive for CD9, a third epitope frequently found on EVs. Also,
they were also negative for 13 epitopes found on the surface of
MSCs (Table 1). Therefore, they probably correspond to the EVs
frequently referred to as exosomes (26–29).
Assay for Efficacy of EVs in Suppressing of Neuroinflammation after TBI.
Quantitative assays for efficacy are critical for the development of
most therapeutics (29). We elected to develop a quantitative assay
for the efficacy of EVs in a model for TBI by ELISAs on brain
homogenates. Initial experiments (Figs. S3 and S4) demonstrated
that, after TBI, levels for the proinflammatory cytokine IL-1β peaked
between 6 and 12 h and that the IL-1β colocalized with GFAP+
astrocytes (Fig. 4A). Therefore, we followed a protocol in which
TBI was produced in mice and IL-1β levels in brain were assayed
12 h after the TBI. Administration of the EVs decreased the levels
of IL-1β in a dose-dependent manner (Fig. 4B). The highest dose
of EVs was more effective than i.v. infusion of 1 million of MSCs
expanded in CCM, apparently because the brains were assayed
12 h after administration of the cells but i.v.-administered MSCs
that are trapped in the lung do not express high levels of TSG-6
until 24 h after infusion (36). The dose of EVs that produced the
largest effect (30 μg of protein and 15 × 109 EVs) was synthesized
by about 1 million MSCs under the conditions used here (Fig. 1G),
but the in vitro and in vivo data are obviously directly comparable.
Of special interest was a result in which the dose of EVs that
produced the largest effect (30 μg of protein and 15 × 109 EVs)
contained only 4 ng of TSG-6 whereas administration of 50 μg of
Fig. 3. Chromatographic isolation and characterization of EVs from the medium. (A) Preparation and characterization of CD63+ EVs from medium of MSCs
incubated as in Fig. 1G. (i) Assay by SDS-electrophoretic gel of medium eluted from anion exchange column with 0.5 M NaCl. Gel was silver-stained. (ii) Assays
of eluted fractions for protein and CD63. (B) Recovery of CD63+ protein from the column was slightly greater than recovery by centrifuging the same samples
at 100,000 × g for 12 h. (C) Assays of eluted fractions by nanoparticle diffusion analysis demonstrated that the mean size of the vesicles ranged from 209 ±
1.8 nm (SEM) to 231 ± 3.2 nm. The three peaks at the lower concentration (ii) were 85, 165, and 236 nm. (Insets) Photos of nanoparticles in the instrument.
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recombinant TSG-6 i.v. was required previously in four models of
induced inflammation in mice (21–23).
After i.v. administration of 30 μg of CD63+ EVs into naive
mice, the EVs were detected by ELISAs of plasma after 5 min,
but they were not detected after 15 min (Fig. S3). Therefore,
they were apparently rapidly distributed to tissues. Low levels of
CD63+ EVs were also detected in plasma 5 min after infusion of
1 × 106 MSCs from donor 6015.
Effects of EVs on Pattern Separation Function and Spatial Learning
Ability After TBI. Because the isolated EVs decreased inflamma-
tion 12 h after TBI, we tested their effects on pattern separation
ability and spatial learning and memory function a month after
TBI (Fig. 5). Pattern separation is proficiency for discriminating
analogous experiences through storage of similar representations
in a nonoverlapping manner (37, 38), and the hippocampus neu-
rogenesis plays a major role in maintaining this function. An
object-based behavioral test demonstrated preservation of the
ability for pattern separation in TBI mice treated with i.v. EVs, in
comparison with TBI mice treated with vehicle exhibiting pattern
separation deficits (Fig. 5D). Furthermore, in a water maze test
(Fig. 5A), TBI mice treated with i.v. EVs learned to find the
concealed platform after three trials as reflected in the decrease
in latency time that became similar to the latency time in control
mice that received sham operations, implying preservation of
spatial learning ability in TBI mice receiving EVs. In contrast,
mice that received vehicle after TBI improved only slightly. There
were no significant differences in memory retrieval function in a
probe test between TBI mice receiving EVs or vehicle because
the number of times mice entered the platform zone and the time
spent in the platform zone (Fig. 5 B and C) were similar between
the two TBI groups, which contrasted with the behavior of control
mice exhibiting greater dwell times in the platform zone.
Discussion
The role of EVs in cellular communication has stimulated renewed
interest in using vesicles for the delivery of therapeutic agents
(26–29). The strategies have included vesicles prepared from
purified components (liposomes), a strategy initiated many years
ago, as well as newer strategies with vesicles prepared by frag-
mentation of cellular membranes and EVs produced by cultured
cells. Each strategy is likely to be ideal for different applications.
EVs produced by cells have the advantage that they may contain
naturally occurring therapeutic cargos and specific cell-targeting
Table 1. Surface epitopes in hMSCs and EVs
Surface epitopes
hMSCs*
EVs*CCM CDPF
hMSC markers
CD29 >99 >99 <1
CD44 >99 >99 <2
CD49c >99 >99 <1
CD49f >99 >99 <1
CD59 >99 >99 2.04
CD73 >99 >99 <2
CD90 >99 >99 <1
CD105 >99 >99 <1
CD146 >99 >99 <2
CD147 >99 >99 <1
CD166 >99 >99 <1
HLA-a, b, c >99 >99 <2
PODXL 95 91 <2
EV markers
CD9 93 99 <1
CD63 48 85 90.6
CD81 >99 >99 79.9
hMSC, human mesenchymal stem/stromal cell.
*Positively stained cells or EVs (% of total) with antibodies indicated in Table S2.
Fig. 4. Dose–response data for suppression of neuroinflammation by EVs
after TBI. (A) Immunochemistry of brain sections demonstrated that TBI in-
creased IL-1β in GFAP+ astrocytes. Sections from brain recovered 12 h after
TBI and sections from region indicated were stained for DAPI, IL-1β, and
GFAP. (B) Dose-dependent decrease in IL-1β after i.v. administration of PBS
or EVs. Amounts varied from 3.5 to 30 μg of protein or 1.8–15.3 × 109 EVs.
PBS or EVs were administered 1 h after TBI, and assays were by ELISA on
homogenates of ipsilateral brain isolated 12 h after TBI. The i.v. adminis-
tration of 1 million MSCs cultured in CCM had little effect, apparently be-
cause they were not fully activated in 12 h to express TSG-6 by embolization
of the lung (21).
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ligands. Also, EVs can be engineered to contain novel cargos and
cell-targeting ligands.
The experiments presented here addressed several issues that
currently limit therapeutic applications of EVs. Two of the issues
are the choice of the producing cells and the culture conditions
under which the cells produce EVs. MSCs are attractive choices of
cells for several reasons. They can be obtained from multiple tis-
sues, including fat, umbilical cord, and synovial membranes (6–8).
The cells from human bone marrow have been the most extensively
studied and, like MSCs from other human tissues, can readily be
expanded in culture (39). However, they are not tumorigenic (40).
Also, they do not undergo spontaneous transformation during ex-
pansion in culture to generate malignant lines, as is observed with
mouse MSCs (41) and as has been overlooked in multiple publi-
cations with murine MSCs (6, 40, 41). Therefore, they are unlikely
to transfer tumorigenic factors in the EVs they produce, a risk
inherent with immortal cell lines. Instead, the EVs produced by
MSCs are likely to transfer therapeutic components, because
MSCs have been shown to have beneficial effects in a large number
of disease models (6, 7) and in a few clinical trials in patients (42–
44). Moreover, the beneficial effects are largely explained by MSCs
being activated by signals from injured cells to transfer a large
number of therapeutic factors, including cytokines, chemokines,
microRNAs, and mitochondria (6, 7, 45, 46). Also, MSCs tend to
home to injured tissues, and some of the EVs they produce may
retain this homing ability. In addition, MSCs are an attractive
source of EVs because of an unusual property of the cells: They
can survive for weeks in culture with medium containing no protein
or growth factors but continue to produce EVs (47–50). During
incubation of MSCs from bone marrow in α-MEM, the cultures
underwent selection with survival of a subpopulation that expressed
genes characteristic of embryonic cells (47). Pochampally and co-
workers subsequently demonstrated that the MSCs incubated in
α-MEM produced EVs, and they extensively characterized the EVs
(48). They also demonstrated that the EVs supported tumor
growth. Phinney et al. (49) demonstrated that EVs produced by
human MSCs under different culture conditions partially rescued
silica-induced fibrosis of lung in mice.
One limitation in using MSCs for producing EVs is the number of
cells that can be obtained (29) becauseMSCs senesce after extensive
expansion in culture (39, 40). Another limitation is that different
preparations vary. The present protocol in part overcame these
limitations by preselecting an initial preparation of bone marrow
MSCs that could be expanded to provide up to 1015 cells from a
small bone marrow aspirate of 2–4 mL (39). The 1015 MSCs are
about 106 times the amount required for the experiments described
here, but it is likely that larger samples of MSCs from bone marrow
or other tissues will be required for clinical therapies. The prepa-
ration was also preselected by the criteria that the cells expressed
high levels of the biomarker TSG-6 mRNA that was highly corre-
lated with the efficacy of the MSCs in suppressing inflammation in
three mouse models (34). As indicated here, the preselected cells
expressed high levels of mRNA for CD63, an observation that may
provide a potency marker for the efficiency of MSCs is producing
EVs. To minimize the variations introduced by culture conditions,
the cells were expanded at low density with a standardized protocol
under which the cells retain most of their progenitor features (39).
Also, to recover EVs, the cells were incubated in a chemically de-
fined protein-free medium that was optimized for growth and pro-
duction of recombinant proteins by CHO cells on a commercial
scale (Invitrogen). Apparently, because it is protein-free, the me-
dium induced stress on the MSCs, but it minimized the cell death
seen with culturing MSCs under other conditions used to produce
EVs (28, 49). The differences in culture conditions may explain why
the medium harvested as a 2,600 × g supernatant did not contain the
large vesicles isolated by Phinney et al. (49).
The experiments were also designed to address two further is-
sues: scalable protocols and quantitative assays for efficacy. To
provide a scalable protocol, we used a chromatographic column to
isolate the EVs. Use of the column provided a 500-fold concen-
tration of the EVs and a protocol that can more readily be scaled
up than protocols than use high-speed centrifugation and related
techniques (29). We addressed the need for an efficacy assay with a
protocol in which EVs were i.v. infused after TBI in mice and IL-1β
levels in brain were measured by ELISA 12 h later. The EVs
produced by human MSCs were effective in the WT mice, an
observation consistent with the expression by human MSCs of
undetectable levels of MHC class II and very low levels of MHC
class I (6, 7). Also, it is consistent with the observation here that the
EVs were HLA-a, -b, and -c negative. In addition, the observation
that human EVs were effective is consistent with previous reports
that i.v. administrations of human MSCs produced therapeutic
effects in immune competent mice (6), including a model for TBI
(36). Therefore, immune reactions to single administrations of
human EVs in mouse models are unlikely to produce complicating
immune reactions; models requiring repeated administrations may
need to be examined more carefully.
Subsequently, we were able to demonstrate that infusion of
the effective dose of the isolated EVs after TBI rescued pattern
separation and spatial learning impairments 1 mo later. Therefore,
the results suggested that, by modulating the initial inflammation
produced by the TBI, the EVs interrupted the self-perpetuating
cycle of tissue destruction and inflammation that largely explains
the chronic effects of TBI (2–5).
At the same time, the results did not resolve several important
issues. The CD63+CD81+ EVs seemed to account for most of
the EVs secreted by the cells, but the data did not exclude the
possibility that a small fraction of the EVs (less than 10% or
Fig. 5. Improved cognitive function after TBI and i.v. EVs. About 1 h after
TBI, each mouse received i.v. PBS or 30 μg of protein (about 15.3 × 109 EVs)
from the pooled peak from the anion exchange column (pooled CM-Q) (Fig.
3 A, ii). Behavior in the water maze was tested 28–33 d after TBI. The pattern
separation test was performed 35 d after TBI. (A) In the water maze, treated
mice with TBI learned to locate the hidden platform with the same latency as
controls after four trials and better than TBI mice that received PBS. There
was no significant effect of the therapy on the number of entries to plat-
form zone (B) or time spent in the platform zone (C) in the probe test.
(D) The treated mice performed better than TBI mice that received PBS in the
pattern separation test.
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20%) were CD63-negative. The results are similar to the results
reported by Vallabhaneni et al. (48), but the data are not directly
comparable because of differences in the conditions used to
produce MSCs and in many of the assays used. A second un-
resolved issue is the molecular mechanism whereby the i.v.-infused
EVs reduced inflammation and rescue cognitive impairments in
the TBI model. The EVs isolated here contained TSG-6, and pre-
vious results indicated that some of—but not necessarily all of—the
antiinflammation effects of MSCs were explainable by the cells
being activated to express TSG-6 (21, 22). However, the amount
of TSG-6 in the effective dose of EVs was less than 1/10,000 the
amount of recombinant TSG-6 required to suppress inflammation
in several animal models. Therefore, the efficacy of the EVs ob-
served here may well be explained by their containing many com-
ponents other than TSG-6. Unfortunately, the technologies to
define the active components of EVs and their effects of EVs on
target cells are still challenging (26–29). For example, sequencing
of the microRNAs and other RNAs in EVs provides data on mil-
lions of potential targets for the microRNAs (48), but it is difficult
to identify those with significant effects on their target cells (48, 50).
Materials and Methods
Details are presented in SI Materials and Methods on all methods, including
culture conditions, chromatographic isolation of EVs, PCR and ELISA assays,
nanoparticle tracking analysis, controlled cortical impact injury, behavioral
studies, and statistical tests. hMSCs were from the Center for Distribution
(medicine.tamhsc.edu/irm/msc-distribution.html) and all animal protocols were
approved by the Texas A&M Animal Care and Use Committee. Human MSCs
were obtained from normal, healthy donors with informed consent under Scott
& White and Texas A&M Institutional Review Boards approved procedures.
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